BayMark operates Opioid Treatment Programs (OTPs) providing medication-assisted treatment (MAT) across the United States and Canada. These programs offer methadone and buprenorphine, supported by counseling and recovery services, to provide a comprehensive, evidence-based treatment option for opioid addiction.
Opioid Treatment Programs (OTPs) have been proven to be clinically effective for the treatment of opioid use disorder. For more than 50 years, methadone has been considered the gold standard in medication-assisted treatment. In the early 2000’s, buprenorphine, often referred to by the brand name Suboxone®, was approved by the FDA for use in treating opioid addiction. Some programs also offer naltrexone, the newest FDA approved medication for the treatment of opioid addiction.